MedTrace Logo

Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea

NCT06620510 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2025-08-15

No results posted yet for this study

Summary

To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea

Conditions

Interventions

BIOLOGICAL

Immuncell-LC

Activated T lymphocyte

BIOLOGICAL

No Interventions

Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).

Sponsors & Collaborators

  • GC Cell Corporation

    lead INDUSTRY

Principal Investigators

  • JinHee Kang · Global Product Development Division

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2024-12-05
Completion
2025-06-13

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06620510 on ClinicalTrials.gov